Splicing targeting approaches highlight actionable vulnerabilities in advanced prostate cancer [22Rv1]
Ontology highlight
ABSTRACT: To investigate if pharmacological inhibition of splicing could uncover novel actionable vulnerabilities in CRPC, we profiled the genome-wide transcriptional changes elicited in 22Rv1 cells by treatment with three drugs that inhibit the splicing through different molecular targets: i. Pladienolide B, that impairs the activity of SF3B1; ii. Indisulam that promote degradation of the splicing factor RBM39; iii. THZ531 inhibits the cyclin dependent kinases (CDK) 12 and 13.
ORGANISM(S): Homo sapiens
PROVIDER: GSE234734 | GEO | 2024/03/06
REPOSITORIES: GEO
ACCESS DATA